LT3230320T - Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną - Google Patents

Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną

Info

Publication number
LT3230320T
LT3230320T LTEP15816631.4T LT15816631T LT3230320T LT 3230320 T LT3230320 T LT 3230320T LT 15816631 T LT15816631 T LT 15816631T LT 3230320 T LT3230320 T LT 3230320T
Authority
LT
Lithuania
Prior art keywords
differentiation
gene
human animals
humanized
cluster
Prior art date
Application number
LTEP15816631.4T
Other languages
English (en)
Lithuanian (lt)
Inventor
Elena BUROVA
Yajun Tang
Ka-Man Venus Lai
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT3230320T publication Critical patent/LT3230320T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP15816631.4T 2014-12-09 2015-12-09 Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną LT3230320T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462089549P 2014-12-09 2014-12-09
US201562106525P 2015-01-22 2015-01-22
PCT/US2015/064626 WO2016094481A1 (en) 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene

Publications (1)

Publication Number Publication Date
LT3230320T true LT3230320T (lt) 2021-01-11

Family

ID=55024286

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP15816631.4T LT3230320T (lt) 2014-12-09 2015-12-09 Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną
LTEP20194168.9T LT3808775T (lt) 2014-12-09 2015-12-09 Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP20194168.9T LT3808775T (lt) 2014-12-09 2015-12-09 Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną

Country Status (27)

Country Link
US (4) US9913461B2 (enExample)
EP (3) EP3230320B1 (enExample)
JP (3) JP2018500896A (enExample)
KR (2) KR102316842B1 (enExample)
CN (2) CN107257624B (enExample)
AU (3) AU2015360667B2 (enExample)
BR (1) BR112017011982A2 (enExample)
CA (1) CA2968675C (enExample)
CY (1) CY1123723T1 (enExample)
DK (2) DK3808775T3 (enExample)
ES (2) ES2982515T3 (enExample)
FI (1) FI3808775T3 (enExample)
HR (2) HRP20202034T1 (enExample)
HU (2) HUE052606T2 (enExample)
IL (3) IL282649B (enExample)
LT (2) LT3230320T (enExample)
MX (1) MX2017007636A (enExample)
NZ (2) NZ770783A (enExample)
PL (1) PL3808775T3 (enExample)
PT (2) PT3808775T (enExample)
RS (2) RS65664B1 (enExample)
RU (1) RU2711729C2 (enExample)
SG (2) SG10202100792XA (enExample)
SI (2) SI3230320T1 (enExample)
SM (2) SMT202400313T1 (enExample)
WO (1) WO2016094481A1 (enExample)
ZA (1) ZA201703263B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20202034T1 (hr) 2014-12-09 2021-02-19 Regeneron Pharmaceuticals, Inc. Neljudske životinje s genom za humanizirani diferencijacijski biljeg cd274
JP6997708B2 (ja) 2015-11-20 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化されたｌｙｍｐｈｏｃｙｔｅ－ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物
JP6843872B2 (ja) 2016-02-04 2021-03-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 操作されたａｎｇｐｔｌ８遺伝子を有する非ヒト動物
RU2749715C2 (ru) 2016-02-29 2021-06-16 Регенерон Фармасьютикалз, Инк. Грызуны, характеризующиеся гуманизированным геном tmprss
WO2018001241A1 (zh) 2016-06-28 2018-01-04 北京百奥赛图基因生物技术有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
CN107815467B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041120A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
CN107815466B (zh) * 2016-08-31 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
DK3507373T5 (da) 2016-08-31 2024-09-02 Biocytogen Pharmaceuticals Beijing Co Ltd Genetisk modificeret ikke-menneskeligt dyr med human eller kimær pd-l1
AU2017367734B2 (en) 2016-12-01 2025-01-09 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-l1 antibodies for immuno-PET imaging
CN109666701B (zh) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
WO2019072241A1 (en) * 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
JP7361031B2 (ja) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
CN109913493B (zh) 2017-12-12 2021-03-16 百奥赛图江苏基因生物技术有限公司 人源化cd3基因改造动物模型的制备方法及应用
CN112105260B (zh) 2018-03-26 2023-04-28 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
SMT202400300T1 (it) 2018-07-16 2024-09-16 Regeneron Pharma Modelli di roditori della sindrome ditra e loro utilizzo
CN110846321B (zh) * 2018-08-21 2021-11-19 中国科学院动物研究所 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途
WO2020081585A1 (en) * 2018-10-15 2020-04-23 The Brigham And Women's Hospital, Inc. The long non-coding rna inca1 and homo sapiens heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) as therapeutic targets for immunotherapy
CN109452229B (zh) * 2018-11-19 2021-10-22 百奥赛图(北京)医药科技股份有限公司 狗源化pd-1基因改造动物模型的制备方法及应用
CN109979539B (zh) * 2019-04-10 2020-10-02 电子科技大学 基因序列优化方法、装置及数据处理终端
WO2022174823A1 (en) * 2021-02-19 2022-08-25 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric cd3 genes
CN112999368A (zh) * 2021-04-09 2021-06-22 广东药康生物科技有限公司 人源化模型进行药效评价方法的建立

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US6485964B1 (en) * 1995-03-20 2002-11-26 Arris Pharmaceutical Corporation Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
AU2001273096B8 (en) 2000-06-28 2005-10-13 Dana-Farber Cancer Institute, Inc. PD-L2 molecules: novel PD-1 ligands and uses therefor
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2243493A1 (en) 2002-07-03 2010-10-27 Ono Pharmaceutical Co., Ltd. Immunopotentiative composition
US20060179501A1 (en) * 2002-12-16 2006-08-10 Chan Andrew C Transgenic mice expressing human cd20
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
JP4936899B2 (ja) * 2003-12-24 2012-05-23 ジー２ インフラメイション ピーティーワイ エルティーディー ヒトまたはヒト化Ｃ５ａＲをコードするポリヌクレオチドを含むトランスジェニック非ヒト哺乳動物
EP1701611B1 (en) 2003-12-24 2011-05-18 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
SI3428191T1 (sl) 2004-10-06 2025-03-31 Mayo Foundation For Medical Education And Research B7-H1 in PD-1 v zdravljenju karcinoma ledvičnih celic
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
EP2889309B1 (en) 2006-03-03 2017-12-27 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of pd-1 or pd-l1
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
KR101629071B1 (ko) 2008-10-08 2016-06-09 인트렉손 코포레이션 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
CN112680475B (zh) * 2008-12-18 2024-11-12 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8354389B2 (en) 2009-08-14 2013-01-15 Regeneron Pharmaceuticals, Inc. miRNA-regulated differentiation-dependent self-deleting cassette
EP2470671B1 (en) * 2009-08-28 2014-12-24 Regeneron Pharmaceuticals, Inc. Antikine antibodies that bind to multiple cc chemokines
JP5874881B2 (ja) 2009-10-06 2016-03-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝子改変されたマウスおよび移植方法
WO2011060357A2 (en) 2009-11-16 2011-05-19 The Ohio State University Engineered xenogeneic cells for repair of biological tissue
LT3279215T (lt) * 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
TR201808011T4 (tr) * 2009-12-21 2018-06-21 Regeneron Pharma Hümanize fc gama r fareleri.
CA2792561C (en) * 2010-04-06 2021-10-26 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
EP2675271B1 (en) * 2011-02-15 2018-06-13 Regeneron Pharmaceuticals, Inc. Humanized m-csf mice
PT2770821T (pt) 2011-10-28 2017-12-18 Regeneron Pharma Ratinhos de complexo principal de histocompatibilidade principal modificados geneticamente
HRP20220616T1 (hr) 2011-10-28 2022-06-24 Regeneron Pharmaceuticals, Inc. Genetski modificirani miš koji eksprimira kimerne molekule glavnog kompleksa histokompatibilnosti (mhc) ii
PL2663575T3 (pl) 2011-10-28 2015-03-31 Regeneron Pharma Humanizowane IL-6 i receptor IL-6
US9644179B2 (en) 2011-11-23 2017-05-09 The Trustees Of The University Of Pennsylvania Use of PDL1 expressing cells to convert T cells into regulatory T cells
EP3763741A1 (en) 2011-11-28 2021-01-13 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
US9845356B2 (en) 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
WO2014031610A1 (en) * 2012-08-21 2014-02-27 Sanofi Methods for treating or preventing asthma by administering an il-4r antagonist
KR102340059B1 (ko) 2012-09-07 2021-12-17 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
US9901082B2 (en) 2012-11-05 2018-02-27 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
KR102369454B1 (ko) 2013-02-20 2022-03-04 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
SG10201706741VA (en) 2013-02-20 2017-10-30 Regeneron Pharma Genetic modification of rats
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
CN110192541B (zh) 2013-02-22 2022-02-18 瑞泽恩制药公司 表达人源化主要组织相容性复合物的小鼠
BR112015026197B1 (pt) * 2013-04-16 2022-12-06 Regeneron Pharmaceuticals, Inc Método para modificação marcada de um lócus genômico de interesse em uma célula de rato pluripotente
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
WO2014197369A1 (en) 2013-06-06 2014-12-11 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
SG11201601184UA (en) 2013-09-23 2016-03-30 Regeneron Pharma Non-human animals having a humanized signal-regulatory protein gene
WO2015077071A1 (en) 2013-11-19 2015-05-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
CN106163273B (zh) 2014-04-08 2020-07-24 瑞泽恩制药公司 具有人源化FC-γ受体的非人动物
NO2785538T3 (enExample) 2014-05-07 2018-08-04
KR102821645B1 (ko) 2014-05-19 2025-06-19 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
US10390522B2 (en) 2014-06-19 2019-08-27 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
MX2017006802A (es) 2014-11-24 2018-01-30 Regeneron Pharma Animales no humanos que expresan el complejo cd3 humanizado.
TR201903891T4 (tr) 2014-12-05 2019-04-22 Regeneron Pharma Bir insanlaştırılmış farklılaşma kümesi 47 genine sahip olan insan dışı hayvanlar.
HRP20202034T1 (hr) 2014-12-09 2021-02-19 Regeneron Pharmaceuticals, Inc. Neljudske životinje s genom za humanizirani diferencijacijski biljeg cd274
JP6997708B2 (ja) 2015-11-20 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化されたｌｙｍｐｈｏｃｙｔｅ－ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物
DK3507373T5 (da) 2016-08-31 2024-09-02 Biocytogen Pharmaceuticals Beijing Co Ltd Genetisk modificeret ikke-menneskeligt dyr med human eller kimær pd-l1

Also Published As

Publication number Publication date
ES2841353T3 (es) 2021-07-08
AU2021286369A1 (en) 2022-01-20
NZ770783A (en) 2024-11-29
KR20210130251A (ko) 2021-10-29
US20160157469A1 (en) 2016-06-09
DK3230320T3 (da) 2021-01-11
JP2021003130A (ja) 2021-01-14
PT3808775T (pt) 2024-07-09
PT3230320T (pt) 2021-01-08
PL3808775T3 (pl) 2024-08-19
IL252695A0 (en) 2017-08-31
LT3808775T (lt) 2024-07-10
KR102316842B1 (ko) 2021-10-25
SI3230320T1 (sl) 2021-02-26
NZ731954A (en) 2024-11-29
SG10202100792XA (en) 2021-03-30
JP7488861B2 (ja) 2024-05-22
CA2968675C (en) 2023-10-17
EP3808775A1 (en) 2021-04-21
US20180160663A1 (en) 2018-06-14
WO2016094481A1 (en) 2016-06-16
CA2968675A1 (en) 2016-06-16
CN107257624B (zh) 2021-07-13
EP4399969A3 (en) 2024-10-30
HRP20240855T1 (hr) 2024-10-11
HUE052606T2 (hu) 2021-05-28
US20240389563A1 (en) 2024-11-28
US12089575B2 (en) 2024-09-17
RS61218B1 (sr) 2021-01-29
EP3230320B1 (en) 2020-10-07
RU2711729C2 (ru) 2020-01-21
SMT202100148T1 (it) 2021-05-07
EP3808775B1 (en) 2024-04-17
US20210105983A1 (en) 2021-04-15
RU2017123754A (ru) 2019-01-10
KR20170101910A (ko) 2017-09-06
CN107257624A (zh) 2017-10-17
CY1123723T1 (el) 2022-03-24
HUE067123T2 (hu) 2024-10-28
KR102457921B1 (ko) 2022-10-25
EP3230320A1 (en) 2017-10-18
HRP20202034T1 (hr) 2021-02-19
JP7145920B2 (ja) 2022-10-03
DK3808775T3 (da) 2024-07-01
FI3808775T3 (fi) 2024-07-02
IL275864A (en) 2020-08-31
US9913461B2 (en) 2018-03-13
IL282649A (en) 2021-06-30
CN113412818B (zh) 2022-11-04
AU2015360667B2 (en) 2021-09-23
US10881086B2 (en) 2021-01-05
CN113412818A (zh) 2021-09-21
SG11201703931QA (en) 2017-06-29
EP4399969A2 (en) 2024-07-17
SI3808775T1 (sl) 2024-08-30
MX2017007636A (es) 2018-03-28
AU2015360667A1 (en) 2017-06-08
RS65664B1 (sr) 2024-07-31
IL282649B (en) 2022-07-01
JP2018500896A (ja) 2018-01-18
AU2021286369B2 (en) 2025-03-27
SMT202400313T1 (it) 2024-09-16
AU2025204751A1 (en) 2025-07-17
BR112017011982A2 (pt) 2018-01-16
RU2017123754A3 (enExample) 2019-06-24
ZA201703263B (en) 2023-02-22
IL252695B (en) 2020-07-30
ES2982515T3 (es) 2024-10-16
JP2022184973A (ja) 2022-12-13
IL275864B (en) 2021-05-31

Similar Documents

Publication Publication Date Title
IL282649A (en) Non-human animals with a humanized gene for differentiation cluster 274
IL286403A (en) Non-human animals having a humanized cluster of differentiation 47 gene
IL287519A (en) Non-human animals with a humanized programmed cell death gene 1
IL258841B (en) Non-human animals with human lymphocyte activation gene 3